利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.024 秒)

    Sulphur containing lipids for use as food supplement or as medicament
    4.
    发明授权
    Sulphur containing lipids for use as food supplement or as medicament 有权
    含硫脂质用作食品补充剂或药物

    公开(公告)号：US08759558B2

    公开(公告)日：2014-06-24

    申请号：US13054212

    申请日：2009-07-13

    申请人： Anne Kristin Holmeide ,  Ragnar Hovland ,  Morten Brændvang

    发明人： Anne Kristin Holmeide ,  Ragnar Hovland ,  Morten Brændvang

    IPC分类号： C11D1/28 ,  A61K31/10

    CPC分类号： C07C323/54 ,  A23L33/12 ,  C07C317/44 ,  C07C323/52 ,  C07C323/55 ,  C07C323/56 ,  C07C323/61 ,  C07C2601/04

    摘要： The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof.The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

    摘要翻译： 本发明涉及通式（I）的脂质化合物：其中R1选自C10-C22烷基，具有1-6个双键的C10-C22烯基和具有1-6个三键的C10-C22炔基; R2和R3相同或不同，并且可以选自不同取代基的一组; Y选自硫，亚砜和砜; X表示羧酸或其衍生物，羧酸酯，羧酸酐或羧酰胺; 或其药学上可接受的盐，复合物或溶剂合物。 本发明还涉及包含这种化合物的药物组合物和脂质组合物，以及用作药物或用于治疗，特别是用于治疗与心血管，代谢和炎性疾病区域有关的疾病的化合物。

    METHODS OF TREATMENT USING LIPID COMPOUNDS
    5.
    发明申请
    METHODS OF TREATMENT USING LIPID COMPOUNDS 有权
    使用脂质化合物治疗方法

    公开(公告)号：US20130345269A1

    公开(公告)日：2013-12-26

    申请号：US13883405

    申请日：2011-11-03

    申请人： Ragnar Hovland ,  Tore Skjæret ,  David Fraser

    发明人： Ragnar Hovland ,  Tore Skjæret ,  David Fraser

    IPC分类号： C07C69/734 ,  C07D263/26 ,  C07C59/60

    CPC分类号： C07C69/734 ,  A61K31/19 ,  A61K31/355 ,  C07C59/60 ,  C07D263/26 ,  A61K2300/00

    摘要： Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

    摘要翻译： 公开了治疗或预防有需要的受试者中的至少一种疾病或病症的方法，包括施用式（I）化合物或其药学上可接受的盐或酯，其中R 1和R 2独立地选自氢原子 或直链，支链和/或环状C 1 -C 6烷基，条件是R 1和R 2不同时为氢或其药学上可接受的盐或酯。 这些疾病或病症可能涉及冠心病（CHD），例如动脉粥样硬化; 代谢综合征/胰岛素抵抗; 和/或血脂异常状况如高甘油三酯血症（HTG），升高的LDL-胆固醇，升高的总胆固醇，升高的Apo B和低HDL-胆固醇。 本公开进一步提供了减少动脉粥样硬化发展的方法。 还公开了包含式（I）化合物的药物组合物。

    Methods of treatment using lipid compounds
    6.
    发明授权
    Methods of treatment using lipid compounds 有权
    使用脂质化合物治疗的方法

    公开(公告)号：US09394228B2

    公开(公告)日：2016-07-19

    申请号：US13883405

    申请日：2011-11-03

    申请人： Ragnar Hovland ,  Tore Skjæret ,  David Fraser

    发明人： Ragnar Hovland ,  Tore Skjæret ,  David Fraser

    IPC分类号： C07C69/734 ,  C07D263/26 ,  C07C59/60 ,  A61K31/19 ,  A61K31/355

    CPC分类号： C07C69/734 ,  A61K31/19 ,  A61K31/355 ,  C07C59/60 ,  C07D263/26 ,  A61K2300/00

    摘要： Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof,wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol.The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

    摘要翻译： 公开了治疗或预防有需要的受试者中的至少一种疾病或病症的方法，包括施用式（I）化合物或其药学上可接受的盐或酯，其中R 1和R 2独立地选自氢原子 或直链，支链和/或环状C 1 -C 6烷基，条件是R 1和R 2不同时为氢或其药学上可接受的盐或酯。 这些疾病或病症可能涉及冠心病（CHD），例如动脉粥样硬化; 代谢综合征/胰岛素抵抗; 和/或血脂异常状况如高甘油三酯血症（HTG），升高的LDL-胆固醇，升高的总胆固醇，升高的Apo B和低HDL-胆固醇。 本公开进一步提供了减少动脉粥样硬化发展的方法。 还公开了包含式（I）化合物的药物组合物。

    NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT
    8.
    发明申请
    NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT 有权
    含有新鲜的含硫脂肪作为食物补充剂或作为药物使用

    公开(公告)号：US20110190395A1

    公开(公告)日：2011-08-04

    申请号：US13054212

    申请日：2009-07-13

    申请人： Anne Kristin Holmeide ,  Ragnar Hovland ,  Morten Brændvang

    发明人： Anne Kristin Holmeide ,  Ragnar Hovland ,  Morten Brændvang

    IPC分类号： A61K31/202 ,  C07C57/03 ,  A61P9/00 ,  A61P3/04 ,  A61P1/16 ,  A61P9/10 ,  A61P3/10 ,  A61P29/00

    CPC分类号： C07C323/54 ,  A23L33/12 ,  C07C317/44 ,  C07C323/52 ,  C07C323/55 ,  C07C323/56 ,  C07C323/61 ,  C07C2601/04

    摘要： The present disclosure relates to lipid compounds of general formula (I) wherein R1 is chosen from a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, and a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from different substituents; Y is chosen from sulphur, sulfoxide, and sulfone; and X is a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride, or a carboxamide; or a pharmaceutically acceptable salt, complex, or solvate thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and methods of using such compounds such as for treating diseases related to cardiovascular, metabolic, and/or inflammatory diseases.

    摘要翻译： 本公开内容涉及通式（I）的脂质化合物，其中R 1选自C 10 -C 22烷基，具有1-6个双键的C 10 -C 22烯基和具有1-6个三价的C 10 -C 22炔基 债券 R2和R3相同或不同并且可以选自不同的取代基; Y选自硫，亚砜和砜; 和X是羧酸或其衍生物，羧酸酯，羧酸酐或羧酰胺; 或其药学上可接受的盐，络合物或溶剂化物。 本公开还涉及包含这些化合物的药物组合物和脂质组合物，以及使用这些化合物的方法，例如用于治疗与心血管，代谢和/或炎性疾病有关的疾病。

    DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS
    9.
    发明申请
    DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS 审中-公开
    DHA衍生物及其作为药物使用

    公开(公告)号：US20100267828A1

    公开(公告)日：2010-10-21

    申请号：US12740377

    申请日：2008-10-30

    申请人： Anne Kristin Holmeide ,  Ragnar Hovland

    发明人： Anne Kristin Holmeide ,  Ragnar Hovland

    IPC分类号： A61K31/232 ,  C07C69/587 ,  C07C67/00 ,  C12P7/64 ,  A61P3/10 ,  A61P3/04 ,  A61P29/00

    CPC分类号： C07C69/587 ,  C07C67/26 ,  C07C67/28 ,  C07C69/63

    摘要： The present disclosure relates to compounds of the general formula (I): wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; or any pharmaceutically acceptable salt, solvate, complex, or pro-drug thereof; and their use as medicaments for the treatment of various diseases and conditions, for example, reduction of elevated triglyceride levels, i.e., hypertriglyceridemia, reduction of non-HDL cholesterol, reduction of glucose and HbA1c, and improvement of insulin resistance. The present disclosure also relates to a pharmaceutical composition comprising compounds of formula (I), as well as to processes for preparing compounds according to formula (I).

    摘要翻译： 本公开内容涉及通式（I）的化合物：其中R 1和R 2相同或不同，并且选自氢原子，羟基，烷基，卤素原子，烷氧基，酰氧基 酰基，烯基，炔基，芳基，烷硫基，烷氧基羰基，烷基亚磺酰基，烷基磺酰基，氨基和烷基氨基; 或其药学上可接受的盐，溶剂化物，复合物或前体药物; 以及它们作为用于治疗各种疾病和病症的药物的用途，例如降低甘油三酯水平升高，即高甘油三酯血症，降低非HDL胆固醇，降低葡萄糖和HbA1c以及改善胰岛素抵抗。 本公开还涉及包含式（I）化合物的药物组合物，以及用于制备根据式（I）的化合物的方法。